RxDoctor Payments DataLook up a doctor →

Jerry Back, MD

Internal Medicine · North Charleston, SCNPI 1821181868

Payments from drug & device makers

$322,096in general payments, 2019–2025

Across 749 payments — averaging $430.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$101K
  • Esperion Therapeutics, Inc.$47K
  • Amarin Pharma, Inc.$45K
  • Corcept Therapeutics$44K
  • Bayer$37K
  • Novo Nordisk$31K
  • plus $17K from 46 others

What the payments were for

  • Consulting fees$27,2158%
  • Speaking & faculty fees$256,74880%
  • Travel & lodging$23,5267%
  • Food & beverage$14,4464%
  • Education$1620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$322,096 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$72,903
Medicare patients
132
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$155,192
FarxigaDapagliflozin Propanediol61$70,220
JardianceEmpagliflozin34$36,239
TrulicityDulaglutide21$33,368
MounjaroTirzepatide25$32,848
Repatha SureclickEvolocumab23$30,563
XareltoRivaroxaban15$24,042
EliquisApixaban25$19,660
VascepaIcosapent Ethyl31$19,434
Xigduo XrDapaglifloz Propaned/Metformin15$18,961
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$13,371
KerendiaFinerenone11$12,859
LinzessLinaclotide11$11,888
OxycontinOxycodone Hcl13$9,335
Testosterone19$3,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31,262$155,19298 claims
AstraZenecaFarxiga$101,444$70,22061 claims
Lilly USA, LLCTrulicity, Mounjaro$136$66,21646 claims
Boehringer IngelheimJardiance$83$36,23934 claims
Johnson & JohnsonXarelto$71$24,04215 claims
PfizerEliquis$86$19,66025 claims
AbbVieLinzess, Synthroid$473$13,29628 claims
BayerKerendia$36,620$12,85911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →